GlaxoSmithKline, CureVac partner to develop COVID-19 vaccine effective against virus variants

Drugmakers GlaxoSmithKline and CureVac said Feb. 3 they have partnered to develop a COVID-19 vaccine that will protect against multiple variants of the virus. 

The companies said they plan to develop multiple mRNA vaccine candidates and hope to develop a single vaccine that will be effective against multiple variants. The vaccine, if approved, may be used to protect people who haven't been vaccinated or as a booster for people who have been vaccinated. 

They said their goal is to get a vaccine candidate approved next year. 

GlaxoSmithKline has agreed to support CureVac's manufacturing of its current COVID-19 vaccine candidate, which is in late-stage clinical trials. GlaxoSmithKline said it will manufacture up to 100 million doses of the vaccine. 

Read the full news release here

More articles on pharmacy:
APhA urges HHS to allow retired pharmacists, pharmacy techs to give vaccines
US COVID-19 vaccinations exceed positive tests for virus, Bloomberg reports
FDA to streamline process to approve vaccines updated for protection against virus variants


© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars